CELL AND GENE THERAPY INSIGHTS

Vector Characterization & Validation

April 2019
Vector Characterization & Validation
Download PDF

Editorial

Process validation for recombinant adeno-associated virus vectors in rare diseases: challenges for MAAs

Process validation for recombinant adeno-associated virus vectors in rare diseases: challenges for MAAs

Catherine Cancian
16 May 2019
Read

Expert Insight

Challenges and opportunities of machine-guided capsid engineering for gene therapy

Challenges and opportunities of machine-guided capsid engineering for gene therapy

Eric D Kelsic, George M Church
20 May 2019
Read
The ongoing evolution and translational potential of novel AAV vectors for human gene therapy

The ongoing evolution and translational potential of novel AAV vectors for human gene therapy

Sabrina Sun, David V Schaffer
16 May 2019
Read
Strategies & technologies for the characterization of adeno-associated virus genomes

Strategies & technologies for the characterization of adeno-associated virus genomes

S E Sullivan, E Menesale, S Bergelson et al.
16 May 2019
Read

Commentary

Analytical Technology Used in the Latest Development of Gene Therapy Candidates

Analytical Technology Used in the Latest Development of Gene Therapy Candidates

Z Li, Z Wu, T Maekawa et al.
16 May 2019
Read

Interview

Advances and shortfalls in AAV vector characterization

Advances and shortfalls in AAV vector characterization

Christine Le Bec
16 May 2019
Read
Preparing an ex vivo gene therapy process for process validation

Preparing an ex vivo gene therapy process for process validation

John Moscariello
16 May 2019
Read
Preparing to navigate European regulatory requirements for gene therapy process validation

Preparing to navigate European regulatory requirements for gene therapy process validation

Sol Ruiz
16 May 2019
Read
Building a LVV characterization and process validation strategy

Building a LVV characterization and process validation strategy

Michael Burnham
16 May 2019
Read